ABSTRACT
BACKGROUND: Ureteroarterial fistula (UAF) is a rare occurrence. It can be difficult to diagnose with a high mortality. We report a case of a recurrent UAF. CASE: A 38-year-old women diagnosed with cervical cancer had undergone pelvic exenteration for severe radiation-induced necrosis with a vesicovaginal and rectovaginal fistula after primary radiation therapy. Hemorrhage into the urinary tract necessitated surgical intervention and vascular repair with a femoral-femoral bypass. Although these measures were effective, the patient died 6 months later following an acute hemorrhage into her conduit. Arteriogram revealed a second UAF. CONCLUSION: When urinary tract bleeding occurs in patients previously diagnosed with a gynecologic malignancy and treated with radiation therapy and extensive surgery with urinary diversion, UAF should be considered in the differential diagnoses.
Subject(s)
Carcinoma, Squamous Cell/surgery , Iliac Artery/pathology , Pelvic Exenteration/adverse effects , Ureteral Diseases/etiology , Urinary Fistula/etiology , Uterine Cervical Neoplasms/surgery , Adult , Carcinoma, Squamous Cell/radiotherapy , Fatal Outcome , Female , Humans , Iliac Artery/diagnostic imaging , Necrosis , Neoplasm Recurrence, Local , Radiation Injuries/surgery , Radiography , Ureteral Diseases/diagnostic imaging , Urinary Fistula/diagnostic imaging , Uterine Cervical Neoplasms/radiotherapyABSTRACT
OBJECTIVES: Activin A is a dimeric protein, composed of two beta-A subunits, that belongs to the TGF-beta family of growth factors. Most primary epithelial ovarian tumors (96%) synthesize and secrete activin protein in vitro and preliminary studies show that serum levels of activin are frequently elevated in women with epithelial ovarian cancer. Our objectives were to expand on studies of serum activin A levels in women with epithelial ovarian cancer and to determine whether levels of activin A correlate with the clinical course of disease. METHOD: Preoperative serum activin A levels were measured in 41 patients with epithelial ovarian cancer. In addition, serum activin A levels were measured in all available postoperative samples from the subset of these patients (n = 26) who had an elevated preoperative serum activin A level. Medical record information was used to compare each patient's serum levels of activin A to the clinical course of disease. RESULTS: Seventy-two percent of the stage III and IV patients (26/36), and none (0/5) of the stage I patients, had an elevated preoperative serum activin level. In postoperative samples, activin A levels were increased with persistent or recurrent (n = 9) stage III or IV ovarian cancer. Activin A levels dropped postoperatively and remained at or below the control level in patients in remission. CONCLUSION: Serum activin A levels correlate with recurrent or persistent disease in patients with epithelial ovarian cancer.
Subject(s)
Growth Substances/blood , Inhibins/blood , Neoplasm Recurrence, Local/blood , Ovarian Neoplasms/blood , Activins , Female , Humans , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/pathologyABSTRACT
Ovarian cancer is the fifth most common malignancy among American women and the fourth leading cause of cancer death. The rapid advances in molecular genetic analysis, presymptomatic detection, and treatment of ovarian cancer are staggering. In this review, both the genetic component and the molecular biology of ovarian cancer are discussed, as well as current recommendations for genetic counseling. It is important for the practicing obstetrician and gynecologist to become familiar with these concepts, for it is he or she who will likely serve as a primary resource of information for these patients.
Subject(s)
Ovarian Neoplasms/genetics , Breast Neoplasms/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis/complications , Female , Genes, BRCA1 , Genes, Tumor Suppressor , Genetic Counseling , Humans , Mutation , Proto-OncogenesABSTRACT
A 23-year-old woman was diagnosed with a 5-cm interstitial pregnancy by transvaginal ultrasound. In addition, she was positive for the human immunodeficiency virus. She underwent laparoscopic cornual excision of the ectopic gestation and was discharged home the next day.
Subject(s)
Laparoscopy , Pregnancy, Ectopic/surgery , Adult , Female , Humans , Male , Pregnancy , Pregnancy, Ectopic/diagnostic imaging , Ultrasonography, PrenatalABSTRACT
We report the case of a 77-year-old white female with adenoid cystic carcinoma of Bartholin's gland. To date only 45 cases of adenoid cystic carcinoma of Bartholin's gland have been reported in the world literature. The longest reported survival is 27 years. This patient was originally diagnosed 33 years ago and presented with her fourth recurrence. She was treated with radical surgery and did well for 6 months, but later died secondary to renal failure. Adenoid cystic carcinoma of the Bartholin's gland is a rare tumor of the vulva. When diagnosed the treatment should be tailored to the patient. When margins are found to be positive, adjuvant radiotherapy may prove to be beneficial.
